

SILENT2

Title: Incidence of silent atrial fibrillation in patients with clinically silent brain ischemic lesions (SILENT2)

Trial number: NCT04449523

Sponsor investigator and Principal Investigator: Prof. Dr. med. L. Roten, Inselspital Bern

PI KSA: Prof. Dr. med. K. Nedeltchev

Status: recruiting

Summary: Atrial fibrillation (AF) is well-recognized as a cause for acute ischemic stroke (AIS) and searched for in clinical practice. However, although AF is associated with silent brain infarctions (SBI), its role in the formation of these lesions is less well established and needs clarification. A multitude of clinical, laboratory, echocardiographic and electrocardiographic parameters are associated with AF. Although no single one of these parameters has sufficient specificity to rule-in AF, their combined use may nevertheless help to identify patients with SBI at highest risk for AF. The study's primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI and it is expected to provide evidence that long term monitoring in subjects with SBI yields similar rates of AF as in patients with AIS. This result would be supportive in introducing long term monitoring to the care pathway in subjects with SBI. Since SBI are more prevalent than AIS and current recommendations very restrictive, this would have a relevant impact on SBI management.